Jan 19 (Reuters) - Shenzhen Hepalink Pharmaceutical Co Ltd :
* Says its controlling Shenzhen-based biotech subsidiary gets approval for new drug Ib/IIa clinical trial in Australia
* The new drug is used for treatment of hyperlipemia
Source text in Chinese: goo.gl/4PZG6r
Further company coverage: (Beijing Headline News)
 